OBJECTIVES: Increasing degrees of renal impairment are associated with higher rates of morbimortality after coronary artery bypass grafting (CABG). This incremental risk has not been well studied in off-pump procedures (OPCAB). We assessed its impact on OPCAB and on-pump CABG (ONCAB). RESULTS: Stages 3-4 patients were older (P < 0.0001), with higher prevalence of diabetes (36.8, 35.0, 39.7 and 74.1%, P < 0.01, 1-4 eGFR groups) peripheral arteriopathy (6.0, 9.0, 15.8 and 29.6%, P < 0.0001) and lower left ventricular ejection fraction (LVEF) (GFR-LVEF correlation: Pearson: 0.12, P < 0.0001). On-pump GFR groups had increasingly higher in-hospital mortality (1.0, 1.2, 3.5 and 15.4%, P < 0.0001), but no differences were observed in OPCAB (5.5, 4.8, 5.4 and 7.1%, P = 0.97). Similar trends on in-hospital morbidity were observed in ONCAB vs OPCAB groups: low cardiac output (P < 0.01), pneumonia (P < 0.01) and stroke (P < 0.05). GFR only predicted mortality in ONCAB patients (odds ratio (OR): 0.96, 95% CI: 0.94-0.98; P < 0.01). Patients with higher eGFR stages had statistically more reduced long-term survival, and this pattern was similar in the three treatment groups, also including the OPCAB group, who had the lowest survival in patients with eGFR stage 4.
INTRODUCTION
Patients with end-stage renal disease are known to be at higher risk for operative death after coronary artery bypass grafting (CABG) [1] . However, the effect of lesser degrees of renal impairment on patient outcomes has not been well characterized [2] [3] [4] . The majority of published studies have utilized serum creatinine as the determinant of the severity of renal failure, but compared with creatinine levels, estimated glomerular filtration rate (eGFR) has been considered as the most reliable index of renal function according to the National Kidney Foundation guidelines [5] . Unfortunately, there is still little information about the effect of varying degrees of preoperative renal dysfunction on the short-term and long-term outcomes in patients undergoing CABG.
Several limitations are also common in some of these studies. Patients on chronic haemodialysis have usually been included in these analyses, but they have a different set of characteristics compared with patients with only compromised renal function [6, 7] . This patient population should be considered as a separate entity because they usually have a diffuse and severely calcified coronary artery disease. Additionally, most studies include patients with urgent and emergent operations as well as elective operations without enough data to be able to assess the time between catheterization and time of surgery. This fact might have an important influence on the outcomes in patients with different degrees of renal impairment [2] [3] [4] [6] [7] [8] [9] .
Moreover, the effect of the avoidance of cardiopulmonary bypass on patients with a spectrum of preoperative renal dysfunction has not been well studied [10] [11] [12] 13] . The real benefit of off-pump CABG (OPCAB) on early and long-term outcomes in these high-risk patients is still controversial. We hypothesized that the impact of non-dialysis-dependent preoperative renal dysfunction may be different in patients undergoing OPCAB or on-pump CABG (ONCAB). Accordingly, the purpose of the current study was to evaluate the impact of increasing degrees of renal impairment on the short-term and long-term outcomes in patients undergoing elective single primary CABG with or without the use of cardiopulmonary bypass. We examined whether OPCAB, compared with ONCAB, was associated with lower mortality or morbidity in those patients with different degrees of preoperative renal dysfunction.
MATERIALS AND METHODS

Study group
A group of 1769 consecutive patients undergoing elective single primary CABG from January 1995 through June 2011 and with complete data on eGFR were initially identified from our institutional Adult Cardiac Surgery Database. Patients undergoing a concomitant cardiac surgical procedure, reoperation or urgent or emergent operations were not considered. Seventeen patients on dialysis were excluded from the initial group. A total of 1752 patients were finally included in this study: 350 received OPCAB and 1402 underwent ONCAB.
Surgical technique
Operative data were retrospectively extracted from medical records, surgery notes and the computer-based databank from the Department of Cardiac Surgery. All patients underwent elective surgery consisting of a single primary CABG procedure. A median sternotomy was used in all patients and the operative technique of revascularization, OPCAB vs ONCAB, was at the discretion of the surgeon. As a general policy, in our institution OPCAB was selectively used by most of the surgeons in elderly patients with a significantly higher risk. Standard techniques were employed in OPCAB patients with conventional coronary stabilization devices and without routine use of intracoronary shunts. The leg-elevation manoeuvre, the heart enucleation aspirating the apex with a suction device and pulling the posterior pericardium with a single stitch were routinely used. When the heart was tilted into a new position, myocardial preload was increased by leg elevation and by administration of fluids. Alternatively, α-adrenergic agents such as phenylephrine or norepinephrine were indicated when the mean arterial pressure remained low, despite optimization of circulating blood volume. Most frequently, proximal anastomoses were performed under a single side-biting aortic clamp after completion of distal anastomoses in most patients. More selectively, proximal anastomoses were performed first depending on the surgeon's preference. An 'aortic non-touch' strategy was preferred in some patients with atheromatous or calcified ascending aorta. Conventional cardiopulmonary bypass (CPB) was utilized for ONCAB and included roller head or centrifugal pumps, membrane oxygenators, cold blood antegrade and retrograde cardioplegia and moderate systemic hypothermia. The target mean pressure on CPB was 60-70 mmHg.
Estimation of GFR and patient subgroups
We estimated GFR on the basis of the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation [14] that was developed in an effort to create a formula more precise than the MDRD formula, especially when actual GFR is >60 ml/min per 1.73 m 2 . The CKD-EPI equation performs better than the Modification of Diet in Renal Disease Study (MDRD) equation, particularly at higher GFR, with less bias and greater accuracy [15] .
Patients were categorized into five groups by eGFR according to National Kidney Foundation guidelines: 
Definitions
Urgent operation was considered when the procedure was performed during hospital stay with an acute episode. Patients undergoing urgent or emergent surgery were not included in this study. Chronic obstructive pulmonary disease was defined as the need for pharmacological therapy for chronic pulmonary compromise or espirometry with moderate-severe obstruction. Previous stroke was defined as history of central neurological deficit >72 h. 'Experienced surgeon in OPCAB' was defined as surgeon with a high rate of OPCAB procedures (>50% of the total number of CABG). Arterial CABG was considered when ≥2 arterial grafts per patient were used. Postoperative acute renal failure was considered in case of ≥2-fold increase in serum creatinine from baseline value or when postoperative renal replacement therapy was necessary.
Data collection and statistical analysis
Most perioperative data were extracted from our surgical database. All-cause long-term mortality was queried using the Social Security Death Index. Preoperative variables and postoperative outcomes were compared between normal and renal insufficiency subgroups. Initially, the impact of increasing stages of renal dysfunction on outcomes was analysed in the global group and in ONCAB and OPCAB subgroups. In addition, a comparison of preoperative characteristics and postoperative outcomes was performed between ONCAB and OPCAB patients. Finally, after controlling for differences in ONCAB vs OPCAB preoperative risk profiles, adjusted morbimortality differences according to eGFR stages and both treatment subgroups were assessed. Statistical analysis was performed using SPSS statistical package 12.0 for Windows (SPSS Corp., Birmingham, AL, USA). Continuous variables were summarized as mean ± SD if normally distributed (Kolmogorov-Smirnov test), on the contrary, median and interquartile ranges were used. Nominal data were presented as frequencies and/or percentages. Univariate analyses of risk factors for in-hospital and longterm mortalities were performed. All variables with P-value <0.10 were entered into a subsequent multivariate analysis.
Stepwise logistic-regression was used to assess the independent impact of the risk factor on the occurrence of in-hospital mortality (selection cut-off set at 0.05). Cox regression analysis was used to identify predictors for late death. Kaplan-Meier curves were generated that provide unadjusted long-term survival estimates for each eGRF stage in each study group. Differences in survival curves were analysed with the log-rank test.
To control for selection bias in the comparison among ONCAB and OPCAB subgroups, a propensity score (PS) analysis was performed. One PS was calculated for each patient from the global group by means of logistic-regression analysis using 20 preoperative and surgical variables including age, sex, body surface area, preoperative risk factors for coronary artery disease and comorbidities, experienced surgeon in OPCAB and year of operation. A saturated model was constructed with all these relevant covariates. PS was defined as the estimated probability of patient assignment to each surgical group (ONCAB vs OPCAB) given all the observed baseline factors and covariables. PS was directly used as a continuous variable to adjust multivariable models to estimate the treatment effect. Additionally, PS 1: 1 matched samples were also created independently, one for the ONCAB and one for the OPCAB subgroups. For each OPCAB patient, we found the ONCAB patient with the closest PS. We were able to find matches for 71% of the OPCAB patients and then we used a second logistic and Cox regression to compute the odds ratio (OR) and hazard-ratio for in-hospital and longterm mortalities between these two matched samples.
RESULTS
Impact of increasing stages of renal dysfunction on outcomes
Patient characteristics and operative data from global, ONCAB and OPCAB groups were classified by eGFR category and are shown in Table 1 . In these three treatment groups, patients with increasing stages of renal dysfunction were older and had a higher prevalence of diabetes and peripheral arteriopathy. Poor left ventricular function was more frequent in Stage 4, and logistic EuroSCORE increased with worsening renal failure. A significant positive eGFR value-left ventricular ejection fraction (LVEF) correlation was observed: Pearson: 0.12, P < 0.0001. On the contrary, the eGFR groups did not differ in gender distribution, other comorbidities such as chronic lung disease or other known preoperative risk factors for coronary artery disease. Despite the fact that the mean number of diseased vessels per patient increased with increasing eGFR stages, particularly in OPCAB patients, the mean number of grafts and the rate of arterial grafting were similar (Table 1) .
A total of 42 patients died after the operation (24 in the ONCAB group and 18 in the OPCAB group). In-hospital mortality and morbidity are represented in Table 2 . As expected, in-hospital mortality and postoperative morbidity were statistically higher with worsening renal failure in the global and ONCAB groups. In contrast, morbimortality was less heavily influenced by the severity of preoperative renal dysfunction in the OPCAB group. Mortality and most postoperative complications were not increased in a similar pattern in OPCAB patients. Although the incidence of postoperative acute renal failure and dialysis increased with higher eGFR stages in the three treatment groups, this increase was lower in OPCAB patients. 490 patients died at the follow-up (418 in the ONCAB group and 72 in the OPCAB group). Unadjusted long-term survival by eGFR status and surgery type (OPCAB vs ONCAB) is represented in Fig. 1 . In-hospital mortality was excluded from this long-term survival analysis in order to assess better the different impact of the off-pump protective effect on early vs late outcomes. As expected, there was a direct relationship between decreasing long-term survival and decreasing eGFR. Patients with higher eGFR stages had statistically more reduced long-term survival, and this pattern was similar in the three treatment groups. Despite the fact that the OPCAB group had a shorter mean follow-up (77 ± 53 months vs 126 ± 54 months, P < 0.0001), OPCAB patients at Stage 4 had the lowest survival.
Comparison between on-pump and OPCAB groups
Preoperative characteristics and postoperative outcomes of unadjusted initial groups. Preoperatively, OPCAB patients had a significantly higher risk. They were generally older (Table 3) and were more likely to have chronic renal failure, peripheral arteriopathy, COPD and previous cerebrovascular accident. Logistic EuroSCORE was also significantly higher compared with patients who received on-pump CABG. However, the coronary artery disease in the OPCAB group had a lower mean number of diseased vessels per patient and consequently, these patients were more likely to receive a lower mean number of grafts. According to this estimated higher risk, the observed in-hospital mortality was significantly increased in OPCAB patients, and this difference was particularly significant in those patients with normal or mild eGFR renal dysfunction. In contrast, there was no statistically significant difference in mortality between surgery types in patients with eGFR stages 3-4 (Table 4) , because OPCAB patients with worse renal function experienced a lower increase in mortality in comparison with ONCAB patients. However, the in-hospital mortality observed in OPCAB patients was higher than the mortality predicted by EuroSCORE and this was evident in the global group and particularly in patients with eGFR stages 1-2. On the contrary, the observed mortality in the ONCAB group was lower and more adjusted to EuroSCORE (with the exception of patients with eGFR stage 4). In the global group, LVEF and eGFR were significant predictors of in-hospital mortality (Table 5 , non-adjusted models). LVEF and eGFR were also significant predictors of in-hospital mortality in the ONCAB group, but in OPCAB patients, eGFR was not significant. Although OPCAB patients had a higher risk, postoperative morbidity was similar in both groups (Table 4) . Interestingly, a trend to decreased morbidity was observed in OPCAB patients with eGFR stages 3-4 in comparison with those patients undergoing ONCAB (nevertheless, no statistically significant differences could be demonstrated with the exception of the incidence of new onset atrial fibrillation). Moreover, the incidence of postoperative atrial fibrillation was significantly reduced in OPCAB patients, particularly in those with more advanced renal failure. In contrast with these early outcomes, patients undergoing OPCAB had a higher risk of all-cause long-term mortality ( Fig. 2A) , particularly those with worse renal function (Fig. 2B) . However, in multivariable Cox regression models for long-term mortality in the global group, neither eGFR nor 'pump-status' (OPCAB vs ONCAB) was significantly associated with higher mortality (Table 6 ). Several preoperative comorbidities were found to be significant independent predictors of this late mortality.
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Preoperative characteristics and postoperative outcomes of the propensity-matched samples. The match selected 250 patients in each treatment group (OPCAB vs ONCAB) who were well matched for most of the preoperative variables and with a mean age of 66 ± 9 and 64 ± 9, respectively. The clinical characteristics of the matched samples are presented in Table 3 (matched OPCAB vs ONCAB groups). As expected with the PS matching technique, there were no significant differences in the preoperative characteristics between both groups. One exception was the age, which was still higher in the OPCAB group. The other exception was serum creatinine, which was even higher in the ONCAB group. Accordingly, in-hospital mortality (12 and 13 patients from ONCAB and OPCAB groups), postoperative morbidity and long-term mortality were not statistically different between these two new groups and are presented in Table 4 (ONCAB vs OPCAB propensity-matched samples) and Fig. 2C (matched OPCAB vs ONCAB groups).
Although not statistically significant, postoperative acute renal failure showed a trend to a higher incidence in patients undergoing on-pump CABG. Additionally, in-hospital mortality was doubled in those ONCAB patients with more advanced renal failure (eGFR stages 3-4), but also without statistically significant differences. After PS matching, eGFR was also a significant predictor of in-hospital mortality in the ONCAB but not in the OPCAB group. In-hospital mortality models in PS-matched groups are presented in Table 5 . No variables were found significantly associated with long-term mortality.
Impact of increasing stages of renal dysfunction on outcomes of propensity-matched samples
After PS, 1:1 matched samples were created from the ONCAB and OPCAB groups, patient characteristics and operative data were classified, as previously, by eGFR category and are given in Table 1 . In these two treatment groups, patients with increasing stages of renal dysfunction were older and had a higher prevalence of diabetes (statistically significant in ONCAB patients). Poor left ventricular function was more frequent in Stage 4, particularly in the ONCAB group. Logistic EuroSCORE increased with worsening renal failure in both groups. As in the previous comparison on the initial unmatched ONCAB and OPCAB groups, in-hospital mortality and postoperative morbidity were statistically higher with worsening renal failure in ONCAB patients. In contrast, mortality and most of the postoperative complications were not increased in a similar pattern in the OPCAB group (Table 2) . Again, morbimortality was less heavily influenced by the severity of preoperative renal dysfunction in this latter group.
DISCUSSION
The present study represents a single-centre cohort of patients comparing early and long-term outcomes of CABG patients with varying levels of preoperative renal dysfunction. As expected, we found that morbidity and in-hospital and long-term mortalities were significantly higher with worsening renal dysfunction. This fact is not surprising as the general preoperative patient risk profile similarly increased with worsening eGFR. But the main finding of the current study is that OPCAB, compared with ONCAB, improved early outcomes, particularly in those patients with higher degrees of renal impairment. Interestingly, morbimortality was less heavily influenced by the severity of preoperative renal dysfunction in OPCAB patients. Although significant preoperative differences were observed between ONCAB and OPCAB subgroups, these results were reproduced after propensity-matched analysis. Moreover, eGFR was an independent predictor for in-hospital mortality in the ONCAB and Global groups but not in OPCAB patients. In contrast, the long-term follow-up demonstrated that patients with worsening renal dysfunction (increasing eGFR stage) showed a similar trend to lower survival in both ONCAB and OPCAB groups. Surprisingly, OPCAB patients with worse renal function (eGFR stage 4) even experienced the highest rate of late death. The off-pump protective effect observed on early outcomes in OPCAB patients with impaired renal function was not evident at the long-term follow-up. Several recent studies have shown improved outcomes with the use of OPCAB techniques in short-term morbidity and mortality, particularly in the high-risk subgroups of patients [10, 13, 16, 17] . Chawla et al. [13] have demonstrated that patients with chronic renal failure experience less in-hospital death or incident renal replacement therapy when treated with OPCAB compared with ONCAB. However, some studies have also demonstrated a worse long-term survival with OPCAB, particularly in those patients with moderate or severe renal dysfunction [10, 12, 18, 19] . Nowadays, the reason for this difference between early and late results is not completely understood, but the potential negative effect of a lower rate of completeness of revascularization with OPCAB, particularly in those patients with worse renal function, may be a possible explanation. This lower incidence of complete revascularization achieved by OPCAB might be particularly more deleterious in those patients with more advanced renal failure. Actually, these patients usually have a more aggressive coronary artery disease with a higher rate of proggression after surgery. Future studies should verify whether this fact is definitely a contributing factor for this worse long-term survival in patients undergoing OPCAB.
Shroff et al. [19] compared early and long-term outcomes of 13 085 dialysis-dependent patients undergoing OPCAB (17.8%) vs ONCAB (82.2%) from the US Renal Data System database. They reported an 8% risk reduction in all-cause mortality associated with OPCAB. The observed survival benefit was clearer in the first year after surgery (OPCAB 70.3 vs ONCAB 68.7%, P = 0.06), but was lost by 2 years postoperatively (OPCAB 55.4% vs ONCAB 55.2%). Similarly, Dewey et al. [18] have also shown that OPCAB in these patients on dialysis have improved early survival, but in contrast, ONCAB patients had improved survival compared with the OPCAB group at the long-term follow-up. Both studies only included patients with end-stage renal disease undergoing haemodyalisis and it is generally accepted that these patients are at high risk for adverse outcomes. On the contrary, outcomes in those patients presenting with a spectrum of different degrees of preoperative renal dysfunction have not been well studied, and the effect of OPCAB in these patients is controversial. Moreover, the majority of published studies have only considered serum creatinine despite the fact that eGFR is the most reliable index of renal function. In a recent study, Boulton et al. [10] have shown that in those patients with normal or mild renal dysfunction or dialysis, long-term all-cause survival was not significantly different between OPCAB and ONCAB. However, in patients with moderate or severe renal dysfunction, long-term survival was significantly improved in the ONCAB group. Patients on chronic haemodialysis have also been included in this study even though they have different characteristics and should be considered as a separate group. Urgent and emergent operations were also included, and the authors were unable to determine the time from preoperative cardiac catheterization to surgical revascularization. Therefore, it is possible that some patients had suffered contrast-induced renal dysfunction after CABG.
In our study, we have used more restrictive inclusion criteria and patients on dialysis or undergoing urgent or emergent operations were not considered because all these factors might alter our overall results. In conclusion, we have shown that in-hospital morbidity and mortality after CABG increase with progressive worsening of renal function in the Global and ONCAB groups. In-hospital mortality and most postoperative complications do not increase in a similar pattern in OPCAB patients. Actually, morbimortality was less heavily influenced by the severity of preoperative renal dysfunction in this latter group. But interestingly, this off-pump advantage in patients with worse renal function was only observed in early outcomes. Patients with higher eGFR stages had statistically more reduced long-term survival, and this pattern was similar in ONCAB and OPCAB groups. OPCAB patients at Stage 4 even had the lowest survival.
Limitations of the study
A retrospective, non-randomized single-centre analysis over a long period of time and with a variety of techniques on patients undergoing CABG is subjected to the effects of selection bias. Nevertheless, no relevant differences among the study groups (ONCAB vs OPCAB) were found after PS adjustment. This statistical methodology has been used in addition to multivariable analyses to reduce the effect of selection bias. The choice of surgical procedure was surgeon-dependent and some surgeons were somewhat more likely than others to select OPCAB. For this reason, the variable 'surgeon' was included in the PS model. The global follow-up period ranged from 7 to 217 months, although for OPCAB patients the mean follow-up period was shorter (77 ± 53 vs 126 ± 54 months, P < 0.0001), but the year of operation was also considered as a variable in this model. Moreover, the learning curve on OPCAB techniques might have influenced our results. Differences regarding perioperative fluid management might also have had an important influence. The mean amount of fluids infused during ONCAB and OPCAB surgery was probably similar, but information about this data was incomplete. The use of antifibrinolytic drugs in ONCAB patients (aprotinin during the initial years and tranexamic acid more recently) might also have had an impact on postoperative renal function. Anyway, our aim was to overcome several important limitations that were frequently present in other studies. Consequently, only non-dialysis-dependent patients undergoing elective single primary CABG have been included and eGFR has been used as the most reliable index of renal function.
APPENDIX. CONFERENCE DISCUSSION
Dr M. Lemma (Milano, Italy): The authors conclude and state at the end of the analysis that in-hospital mortality and morbidity increased with worsening of renal function in on-pump patients but not in OPCAB patients.
I have two questions for you, Dr Fuster. The first one is related to the number of procedures performed per year. In the analysis, if you split your whole series for 16 years, you see that the average number of OPCAB patients was 22 per year and the number of on-pump patients was 88 per year. I would like to know something more about your definition of an expert surgeon in OPCAB surgery in the sense that you define a surgeon as expert if he performs more than 50% of his procedures off-pump.
The second question is related to the number of patients who crossed from off-pump to on-pump. In the description of your technical details, you state that you didn't use any heart positioner or coronary shunts. In my opinion, this technique is not a guarantee of haemodynamic stability during the procedure, particularly if these patients were at high risk. So my question is, how many patients crossed from off-pump to on-pump and how did you consider these patients in your analysis?
Dr Garcia Fuster: The first question was about the number of patients undergoing CABG per year and the percentage of OPCAB performed. We have been very restrictive in our inclusion criteria, as I have commented before. The mean number of OPCAB cases per year was around 30% of all CABG. And in the whole period of the study, the number of OPCAB patients has varied. As a matter of time, I didn't show a graph about the incremental performance of OPCAB in our experience. But the percentage of OPCAB in the global CABG group will be around 30% in our institution. But the patients that we have presented here are a very selective subgroup, because we have been very restrictive in the inclusion criteria. We have avoided reoperations. We have avoided urgent surgery because we have concerns about contrast-induced renal failure if the cardiac catheterization is quite close to the date of the operation. This is one of the most frequent limitations of several of the studies. And we have avoided associated procedures. So the number of patients presented here is not representative of the whole group of CABG patients that have been operated on during this period of time.
The 'experienced surgeon in OPCAB' has been defined arbitrarily as a surgeon with 50% of procedures performed OPCAB.
Finally, the other question is the conversion to on-pump from OPCAB. The percentage of conversion in this retrospective study has been quite difficult to assess, so we have excluded this data from our analysis. We don't use intracoronary shunts routinely. We use a type of vessel loop to control the coronary artery and avoid the use of shunts. Our rate of conversion nowadays, but this is not from this presentation, is really very low, under 1% of our procedures, and most frequently it is an elective conversion, not an emergency conversion.
Dr Lemma: So the question is how many patients crossed from off-pump to on-pump, because if these patients were at high risk with very low renal function, you crossed patients at high risk to on-pump treatment. In so doing, your results could be biased.
Dr Garcia Fuster: This is one of the limitations of these types of retrospective observational studies. This is not an intention-to-treat study. Of course, the final OPCAB group consists of the patients who underwent the OPCAB technique.
Dr L. Sajja (Hyderabad, India): We have carried out subgroup analysis of patients with varying degrees of renal insufficiency (GFR groups) who underwent OPCAB. Even with the OPCAB, the stage III and stage IV patients with renal insufficiency had bad outcomes. So comparing those who are in the risk group, what do you think?
Dr Garcia Fuster: I saw your very nice presentation. In our case, and probably in other publications, chronic renal failure is an important factor of prognostic relevance, not the presence of chronic renal failure but severity of renal failure. We have observed a clear relation of morbidity-mortality with increasing severity of renal failure. We have used this parameter or measure, that is, glomerular filtration rate, because one important limitation is the use of creatine clearance. In my opinion, glomerular filtration rate is a very important measure to assess more properly the impact of chronic renal failure on these patients.
Dr P. Kappetein (Rotterdam, Netherlands): Do you have a theory as to why off-pump surgery does not offer any protection for patients with end stage renal disease? What is your physiological explanation for this?
Dr Garcia Fuster: We found a discrepancy with respect to protection in early vs. long-term results, morbidity and mortality. I don't know the exact answer to this question. We can consider several hypotheses, for example, the impact of incompleteness of revascularization in these critical patients. When the coronary artery disease is more severe and more progressive, perhaps a lesser completeness of revascularization with OPCAB had an important impact on this subgroup of patients. But this is only a hypothesis. We are going to look for this hypothesis in the future.
Dr Kappetein: So you would argue that bad left ventricular function leads to low cardiac output and that this impacts renal function. Is that your explanation?
Dr Garcia Fuster: Well, I think that during the first 30 days or considering in-hospital outcomes, the avoidance of pump is relevant, it might be very important in these patients, but the concern is the benefit at long-term followup. And I cannot explain why this initial OPCAB benefit on morbidity and mortality is not maintained during long-term follow-up, especially in stage IV patients with moderate or severe renal failure.
